After buying BlueRock Therapeutics outright last year, the Leverkusen-headquartered group has put down $2bn up front to acquire another cell and gene therapy specialist in Asklepios BioPharmaceutical.

Biopharma executives discussed their strategies for treating chronic diseases during the Cell and Gene Meeting on the Mesa, including R&D and regulatory considerations.

The health care and crop science conglomerate will pay up to $10.9bn to resolve most Roundup claims, but still has capital to do bolt-on deals like last year’s BlueRock cell therapy buy.

The health care and crop science conglomerate will pay up to $10.9bn to resolve most Roundup claims, but still has capital to do bolt-on deals like last year’s BlueRock cell therapy buy.